JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Outcome of Inversion 16 in TKD Positive and Negative Acute Myeloid Leukemia Patients
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Outcome of Inversion 16 in TKD Positive and Negative Acute Myeloid Leukemia Patients
Shahab, Sadaf; Zahid, Danish; Ahmed, Shariq; Nadeem, Muhammad; Farzana, Tasneem; Taj, Mehwesh; Ahmed, Nuzhat; Shamsi, Tahir S;
  PDF(new window)
 Keywords
 Language
English
 Cited by
 References
1.
Abu-Duhier FM, Goodeve AC, Wilson GA, et al (2001). identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol, 113, 983-8. crossref(new window)

2.
Ahmad F, Mohota R, Sanap S, Mandava S, Das BR (2014). Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype indian acute myeloid leukemia patients. Asian Pac J Cancer Prev, 15, 1247-53. crossref(new window)

3.
Frohling S, Schlenk RF, Breitruck J, et al ( 2002). Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 100, 4372-80. crossref(new window)

4.
Ishfaq M, Malik A, Faiz M, et al (2012). Molecular characterization of FLT3 mutations in acute leukemia patients. Asian Pac J Cancer Prev, 13, 4581-5. crossref(new window)

5.
Janke H, Pastore F, Schumacher D, et al (2014). Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia. PLoS ONE, 9, 89560 crossref(new window)

6.
Kottaridis PD, Gale RE, Frew ME, et al (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-9. crossref(new window)

7.
Mead A J, Linch DC, Hills RK (2007). FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia, Blood, 110, 1262-70 crossref(new window)

8.
Mukda E, Pintaraks K, Sawangpanich R, Wiangnon S, Pakakasama S (2011). FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia. Asian Pac J Cancer Prev, 12, 1827-31

9.
Nakao M, Yokota S, Iwai T, et al (1996). Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 1911-8.

10.
Renneville A, Abdelali RB, Chevret S, et al (2014). Clinical impact of gene mutations and lesions detected by SNParray karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial. Oncotarget, 5, 916-32. crossref(new window)

11.
Shahab S, Shamsi T, Ahmed N (2012). Molecular involvement and prognostic importance of Fms-like tyrosine kinase 3 in acute myeloid leukemia. Asian Pac J Cancer Prev, 13, 4203-08 crossref(new window)

12.
Su L, Gao SJ, Tan YH, Han W, Li W (2013). Associations between age, cytogenetics, FLT3-ITD, and marrow leukemia cells identified by flow cytometry. Asian Pac J Cancer Prev, 14, 5341-44 crossref(new window)

13.
Thiede C, Steudel C, Mohr B et al (2002). Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-35. crossref(new window)